Association of high circulating testosterone with increased glycaemic variability in type 2 diabetes: A cross‐sectional study in China

Abstract

Background: Testosterone affects insulin resistance, but the effect of testosterone treatment on type 2 diabetes (T2D) remains controversial. We aimed to investigate the association between circulating total testosterone (TT) and glycaemic variability using continuous glucose monitoring (CGM) in patients with T2D. Methods:A total of 248 men with T2D were enrolled in the study. Clinical characteristics and plasma for glycated haemoglobin (HbA1c) and C-peptide assessment were collected. TT was measured using a chemiluminescent immunometric assay.All patients were subjected to a 3-day CGM before making adjustments for hypoglycaemic therapy.Results: TT positively correlated with the standard deviation of mean blood glucose (SDBG) (P < 0.05), especially in older patients. Linear regression analysis showed that SDBG was associated with HbA1c (β = 0.354, P < 0.001) and TT (β = 0.164, P = 0.008) after adjusting for age, duration of diabetes, body mass index, fasting/postprandial C-peptide, and use of different hypoglycaemic drugs. The cut-off value of TT for predicting glycaemic variability was 14.76 mmol/L according to receiver operating characteristic (ROC) analysis. SDBG, the coefficient of variation, the incremental area under the curve of glucose (AUC) > 10 mmol/L, and AUC night were increased in the group with TT > 14.76 nmol/L (P < 0.01 for all variables). Body mass index and fasting/postprandial C-peptide were lower in the group with TT > 14.76 nmol/L than in the group with TT ≤ 14.76 nmol/L (P < 0.05).Conclusions: Circulating TT levels should be assessed in patients with T2D in addition to HbA1c for predicting glycaemic variability. More frequent blood glucose monitoring or CGM is suggested for patients with T2D and high testosterone levels.Clinical trials registration: NCT03519529, ClinicalTrials.gov KEYWORDS glycaemic variability, testosterone, type 2 diabetes Bo Ding and Rui Sun contributed equally to this article.

Rapid Changes in Serum Testosterone in Men With Newly Diagnosed Type 2 Diabetes With Intensive Insulin and Metformin

“…The mechanism remains unclear (6). We previously reported that testosterone levels were significantly lower in men with T2DM using metformin than in men not using metformin in a cross-sectional study (7).…”

Diabetes technology and sexual health: which role?

“…The authors found no significant differences in TIR, time above range (TAR, > 140 mg/dL), time below range (TBR, < 70 mg/dL), estimated HbA1c, area under the curve (AUC) for blood glucose values above and below the target during the intervention period. A previous study conducted by Ding et al speculated that increasing testosterone levels in hypogonadal men with DM could lead to an increase in glycemic variability after TRT [ 36 ], but the analysis of data from a the CGM highlighted no significant deterioration of any parameters.…”

Association of Acarbose with Decreased Muscle Mass and Function in Patients with Type 2 Diabetes: A Retrospective, Cross-Sectional Study

“…Our sample size calculation was based on our previous cross-sectional study [27]. Acarbose was used by 32 of 248 patients.…”